# US 2006/0153845 A1 · Method for correcting immune respones and medical agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153845 A1
- Document ID: US20060153845A1
- Status: Published application
- Kind: A1
- Application number: 10/522,651
- Filed: 2002-08-02
- Published: 2006-07-13
- Earliest claimed: 2002-08-02
- Inventors: Oleg Epshtein; Evgeny Goldberg; Alexandr Dygay
- Web page: https://patentgrep.com/patent/US20060153845A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/244: {Interleukins [IL]}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The principle of the present invention is the use of an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to cytokines implicated in the course of inflammation, including autoimmune inflammation, the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to the homeopathic technology. It is possible to use a mixture of activated forms of antibodies to various cytokines involved in the course of the inflammatory process. In addition, employed as a medicament for correcting pathologic immune reactions based on antibodies to the tumor necrosis factor alpha (TNF-α) can be an activated form of antibodies to TNF-α obtained by multiple consecutive dilutions and exposure to external factors; activation preferably being performed in accordance with the homeopathic technology, and the forms preferably being applied in a mixture of various, predominantly centesimal, homeopathic dilutions.

## Claims

### Claim 1

A method of correcting pathologic immune reactions by administering antibodies to cytokines characterized by the use of activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to cytokines involved in the course of inflammation, including autoimmune inflammation, the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably following the homeopathic technology.

### Claim 2 (depends on 1)

A method of treatment according to claim 1 characterized by the use of a mixture of activated forms of antibodies to various cytokines involved in the course of the inflammatory process.

### Claim 3

A medicament for correction of pathologic immune reactions based on antibodies to tumor necrosis factor alpha (TNF-α) characterized by the presence of an activated form of antibodies to TNF-α obtained by multiple consecutive dilutions and exposure to external factors, preferably following the homeopathic technology.

### Claim 4 (depends on 3)

A medicament according to claim 3 characterized by obtaining antibodies with the use of human or heterologous tumor necrosis factor alpha (TNF-α), including a recombinant factor.

### Claim 5 (depends on 3, 4)

A medicament according to claim 3 or 4 characterized by containing a mixture of various, mostly centesimal, homeopathic dilutions.
